Weight Loss Specific Brands: Mounjaro vs Wegovy/Ozempic Mounjaro was FDA-approved in May 2022 for adults with type 2 diabetes, while Zepbound received approval in November 2023 for chronic weight management
Anesthesia and glucagon-like peptide-1 receptor agonists: proceed with caution
It found that participants taking the medication semaglutide, the active ingredient in brands including Wegovy and Ozempic, had a 20% lower risk of heart attack, stroke, or death due to cardiovascular disease
The connections between metabolic health, inflammation, aging, and body composition are becoming clearer with each new study, and GLP-1 receptor agonists sit at the intersection of multiple research pathways
However, for weight loss and diabetes medications, semaglutide represents the long end of the spectrum
We recommend Semaglutide GLP-1 as part of your weight loss regimen only when lifestyle changes and other weight management strategies have not yielded the desired results